Treatment of Depressive Disorders with and without Medication - A Naturalistic Study

Objective: Although randomized clinical trials are the standard method for comparing the efficacy of various depression treatments, the external validity and generalizability of findings obtained by this approach can be questioned for several reasons. In this naturalistic study, we compared the effectiveness of treatments conducted by psychiatrists and clinical psychologists without prescription of drugs to treatments by psychiatrists and physicians using antidepressant agents in patients with depressive disorders in a representative sample of the normal population. Our assumption was that this sample is more representative for subjects treated for depressive disorders than subjects included in controlled trials. Methods: In a post hoc analysis, the health status of depressed patients under treatment for major, minor or recurrent brief depression with medication (20 patients) and without medication (30 patients), and untreated depressed subjects were compared over a one-year period using SCL-90-R depression scale scores. Results: At baseline, the two treatment groups were comparable in terms of diagnosis and severity of symptoms. Treatment effects were relatively small; patients treated with antidepressants tended to improve, whereas patients treated without drugs deteriorated slightly over one year. Seven years later, treated and untreated subjects no longer differed. Conclusion: The results are consistent with previous studies on usual care of depressed patients showing low response rates for non-standardized treatments outside of research settings. Despite a number of methodological shortcomings (small sample size, heterogeneity of subjects and treatments, unusual rating instruments), the results presented here are unique, and provide relevant insight into usual care of depressed patients. This study underlines the importance of standardized psychotherapy and pharmacotherapy in routine practice, of studies investigating the transferability of results of outcome studies across clinical populations, and of quality assurance in primary care psychiatry.

References

• 1 American Psychiatric A ssociation. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Revision). Am J Psychiatry 2000: 157
• 2 Angst J. Die depressive Verstimmung als Schaltstelle psychiatrischer Störungen. In: Hell D, ed Ethologie der Depression. Stuttgart; Fischer 1993: 1-15
• 3 Angst J, Dobler-Mikola A, Binder J. The Zurich Study - A prospective epidemiological study of depressive, neurotic and psychosomatic syndromes.  Eur Arch Psychiatr Neurol Sci. 1984;  234 13-20
• 4 Antonuccio D O, Danton W G, DeNelsky G Y, Greenberg R P, Gordon J S. Raising questions about antidepressants.  Psychother Psychosom. 1999;  68 3-14
• 5 Birkenhager T K, Moleman P, Nolen W A. Benzodiazepines for depression? A review of the literature.  Int Clin Psychopharmacol. 1995;  10 181-95
• 6 Derogatis L R. Administration, Scoring and Procedures Manual-I for the R (revised) version and other instruments of the Psychopathology Rating Scale Series. Baltimore; Johns Hopkins School of Medicine 1977
• 7 DeRubeis R J, Gelfand L A, Tang T Z, Simons A D. Medications versus cognitive behavior therapy for severely depressed outpatients: megaanalysis of four randomized comparisons.  Am J Psychiatry. 1999;  156 1007-13
• 8 Elkin I, Gibbons R D, Shea M T, Sotsky S M, Watkins J T, Pilkonis P A,. et al . Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program.  J Consult Clin Psychol. 1995;  63 841-7
• 9 Elkin I, Shea M T, Watkins J T, Imber S D, Sotsky S M, Collins J F,. et al . National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments.  Arch Gen Psychiatry. 1989;  46 971-82
• 10 Fisher S, Greenberg R P. How sound is the double-blind design for evaluating psychotropic drugs?.  J Nerv Ment Dis. 1993;  181 345-50
• 11 Frank E, Rucci P, Katon W, Barrett J, Williams J W, Oxman T ,. et al . Correlates of remission in primary care patients treated for minor depression.  Gen Hosp Psychiatry. 2002;  24 12-19
• 12 Greenberg R P, Bornstein R F, Greenberg M D, Fisher S. A meta-analysis of antidepressant outcome under ”blinder” conditions.  J Consult Clin Psychol. 1992;  60 664-9; discussion 670 - 7
• 13 Jacobson N S, Truax P. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research.  J Consult Clin Psychol. 1991;  59 12-19
• 14 Quitkin F M, Rabkin J G, Gerald J, Davis J M, Klein D F. Validity of clinical trials of antidepressants.  Am J Psychiatry. 2000;  157 327-37
• 15 Rush A J. Research and clinical practice: bridging the gap.  Curr Opin Psychiatry. 1994;  7 3-4
• 16 Schulberg H C, Block M R, Madonia M J, Scott C P, Rodriguez E, Imber S D,. et al . Treating major depression in primary care practice. Eight-month clinical outcomes.  Arch Gen Psychiatry. 1996;  53 913-9
• 17 Schulberg H C, Katon W, Simon G E, Rush A J. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines.  Arch Gen Psychiatry. 1998;  55 1121-7
• 18 Sherbourne C D, Wells K B, Duan N, Miranda J, Unutzer J, Jaycox L ,. et al . Long-term effectiveness of disseminating quality improvement for depression in primary care.  Arch Gen Psychiatry. 2001;  58 696-703